Revelation Biosciences (REVBW) Financials

Revelation Biosciences (NASDAQ: REVB) remains a pre-revenue biotechnology company with substantial research spending and persistent cash burn. The company reported no revenue in each of the periods provided, while continuing to fund operations primarily through equity and other financing activities.

Financial results weakened sequentially in the first half of 2026. Net loss increased from $3.0 million in Q1 2026 to $3.3 million in Q2, compared with losses of $1.9 million in Q3 2025 and $2.5 million in Q4 2025. Operating expenses also rose from $1.8 million in Q4 2024 to $3.7 million in Q2 2026, reflecting increased investment in both research and development and general corporate activities.

• Cash reserves remain meaningful: REVB held $11.5 million in cash and equivalents at June 30, 2026. Although down from $14.1 million at the end of Q1, the balance provides financial flexibility relative to its quarterly operating cash burn.
• Strong short-term liquidity: Current assets of $11.7 million exceeded current liabilities of $1.9 million by a wide margin, producing a current ratio of approximately 6.2. This reduces near-term balance-sheet pressure.
• Positive equity position: Total shareholders’ equity was $10.1 million at the end of Q2 2026, compared with $3.8 million in Q2 2025. Total liabilities were relatively modest at $2.4 million.
• Financing has supported operations: REVB raised approximately $9.9 million through financing activities during the first half of 2026, including $6.7 million in Q1. This funding helped offset operating losses and supported cash reserves.
• Operating cash burn remains relatively consistent: Cash used in operating activities was $2.6 million in Q2 2026, following $3.2 million in Q1 and $2.0 million in Q4 2025. At the Q2 burn rate, the existing cash balance would cover roughly four to five quarters before additional financing, although actual runway will depend on future spending.
• Research spending is increasing: Research and development expense rose to $1.9 million in Q2 2026 from $1.4 million in Q1 and $965,000 in Q4 2025. This could support clinical development, but it also increases the company’s funding requirements.
• No commercial revenue has been reported: Revenue was $0 in every income statement period provided. REVB therefore has no operating revenue to offset research, development and administrative costs.
• Losses are trending higher: Net losses increased in each quarter from Q3 2025 through Q2 2026, reaching $3.3 million. Operating income was negative $3.7 million in Q2 2026, and other income of $339,000 only partially reduced the loss.
• Continued dependence on external capital: Operating activities consumed cash in every reported quarter. Financing inflows, including equity-related transactions, have been essential to maintaining liquidity, creating potential dilution and refinancing risk for existing shareholders.
• Common-shareholder results remain pressured: Q1 2026 included $5.7 million of preferred stock dividends, causing the loss attributable to common shareholders to reach $8.7 million. Weighted-average shares have also fluctuated sharply across periods, making earnings-per-share comparisons less meaningful and highlighting capital-structure risk.

Overall, REVB’s balance sheet is stronger than it was in mid-2025, but the improvement has largely come from financing rather than business operations. The key issues for investors are the absence of revenue, rising operating expenses, increasing quarterly losses and the company’s ongoing need to raise capital to fund development.